Stealth BioTherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Stealth BioTherapeutics's estimated annual revenue is currently $9.3M per year.
- Stealth BioTherapeutics received $100.0M in venture funding in June 2018.
- Stealth BioTherapeutics's estimated revenue per employee is $120,779
- Stealth BioTherapeutics's total funding is $100M.
Employee Data
- Stealth BioTherapeutics has 77 Employees.
- Stealth BioTherapeutics grew their employee count by 24% last year.
Stealth BioTherapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Legal Counsel | Reveal Email/Phone |
2 | Chief R&D Officer | Reveal Email/Phone |
3 | VP, Clinical Development | Reveal Email/Phone |
4 | SVP, Pharmaceutical Sciences and Technical Operations | Reveal Email/Phone |
5 | VP, Clinical Operations | Reveal Email/Phone |
6 | VP, Clinical Development | Reveal Email/Phone |
7 | VP Quality Assurance | Reveal Email/Phone |
8 | Associate Director Expanded Access Programs and Registry | Reveal Email/Phone |
9 | Associate Director, Non-clinical program management | Reveal Email/Phone |
10 | Executive Director | Reveal Email/Phone |
Stealth BioTherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Stealth BioTherapeutics?
Our Mission Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet need our programs seek to address. We collaborate with top-tier academic and medical institutions, scientific thought leaders, and clinical key opinion leaders in developing the first generation of targeted therapies focusing on mitochondrial dysfunction as it presents in these rare genetic diseases and common diseases of aging. With these collaborative efforts, we continue to advance our platform of late-stage clinical programs and novel pipeline candidates.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$100M
Total Funding
77
Number of Employees
$9.3M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Stealth BioTherapeutics News
BOSTON, April 11, 2022 /PRNewswire/ -- Stealth Biotherapeutics Corp (Nasdaq: MITO) (the "Company"), a clinical-stage biotechnology company...
Stealth BioTherapeutics announced that its signature treatment, elamipretide, was awarded Orphan Drug Designation for the treatment of...
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases...
Other Companies in Newton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.9M | 77 | 3% | N/A |
#2 | $15M | 77 | 0% | N/A |
#3 | $11.9M | 79 | -1% | N/A |
#4 | $23.5M | 81 | -10% | N/A |
#5 | $20.6M | 81 | 5% | N/A |
Stealth BioTherapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-06-19 | $100.0M | Undisclosed | Pivotal Beta | Article |